Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
HOME > REGULATORY
REGULATORY
- MHLW Taking Public Comments on OTC Access to Emergency Contraceptives
January 6, 2023
- MHLW Eyes April Proposal to Push Generic Industry Shake-Up: Asst. Vice Minister
January 6, 2023
- SCARDA to Fund Vaccine Development by KM Biologics, University of Tokyo for Priority Infectious Diseases
January 6, 2023
- “Pseudonymized Medical Info” to Be Created to Fuel Healthcare Data Use in Filing
January 5, 2023
- Revise Assessment Scheme for Deaths after COVID Shots: MHLW Panel Members
December 28, 2022
- No Add'l Safety Measures for Xocova Needed “at This Time”: MHLW Panel
December 28, 2022
- Japan’s Drug Production Contracts 0.9% to 9.2 Trillion Yen in 2021: MHLW
December 28, 2022
- PMDA Says “Slow Cartagena Review” Is Urban Legend, Set to Dispel Misconception
December 27, 2022
- Rx-to-OTC Switching of Morning After Pills Needs Cautious Approach: Lawmakers
December 27, 2022
- 1.1 Billion Yen for Revenue Guarantee System for Antibiotics: FY2023 Budget
December 27, 2022
- Funding for Drug Supply Info System Nixed for 2nd Year: FY2023 Budget
December 27, 2022
- Japan Approves Sanofi’s PD-1 Inhibitor, Teikoku’s Donepezil Tape and More
December 26, 2022
- Chuikyo Recommends Add-On Fee Premiums Related to Drug Supply Issues
December 26, 2022
- PMDA to Add 4 Staff to Expand Orphan Designation Program: FY2023 Budget
December 26, 2022
- MHLW’s FY2023 Budget Totals 33.2 Trillion Yen
December 26, 2022
- Japan Cabinet OKs Record Social Security Budget for FY2023
December 26, 2022
- MHLW Panel OKs 70 More Health Damage Claims for COVID-19 Vaccines
December 26, 2022
- Japan’s Reform Timeline Sees Major Updates for Text on Drug Pricing Overhaul
December 23, 2022
- Japan Deregulation Panel Proposes Two-Step Approval Scheme for SaMD
December 23, 2022
- PMDA to Develop Overseas PR Strategy to Woo Overseas Biotechs
December 23, 2022
ページ
The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…